MeiraGTx Receives FDA Breakthrough Therapy Designation for Gene Therapy Treating Radiation-Induced Dry Mouth
Key Insights
The FDA granted Breakthrough Therapy Designation to MeiraGTx's AAV2-hAQP1 gene therapy for treating Grade 2 and Grade 3 radiation-induced xerostomia (search) in cancer patients.
The designation was supported by 3-year data from a Phase 1 dose escalation study, with the Phase 2 AQUAx2 trial currently enrolling final patients.
MeiraGTx anticipates potential BLA filing in the first half of 2027 and US market launch targeted for early 2028.
The FDA has granted Breakthrough Therapy Designation to MeiraGTx Holdings plc's AAV2-hAQP1 gene therapy for treating Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract. The designation represents a significant regulatory milestone for the clinical-stage genetic medicines company's lead program addressing radiation-induced dry mouth.
"We are delighted to have been awarded Breakthrough Designation for our AAV2-hAQP1 treatment," said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. The breakthrough application was supported by 3-year data from the Phase 1 dose escalation study, which the company plans to present at a program update on April 16th, 2026.
Clinical Development Progress
The breakthrough designation adds to the Regenerative Medicine Advanced Therapy (RMAT) designation previously granted by the FDA for AAV2-hAQP1. MeiraGTx has aligned with the FDA on clinical requirements for the Phase 2 AQUAx2 study (NCT05926765) to support a potential Biologics License Application (BLA), with the primary endpoint being the change from baseline in the Xerostomia Questionnaire at 12 months following the one-time treatment.
The company is currently enrolling final patients in the Phase 2 trial and anticipates data 12 months after the last patient is treated. MeiraGTx projects a potential BLA filing in the first half of 2027, with potential approval around the end of 2027 and US launch targeted for early 2028.
Forbes noted "huge enthusiasm about our Phase 2 AQUAx2 study in the RIX community, amongst physicians and patients," highlighting the significant unmet medical need in this patient population.
Strategic Partnerships Drive Pipeline Advancement
MeiraGTx executed two major strategic collaborations in 2025 that brought immediate non-dilutive financing and potential significant near-term financial milestones. The company signed a collaboration with Eli Lilly and Company focused on the AAV-AIPL1 program for treating LCA4 (search), one of the most severe forms of inherited retinopathies.
Under the Lilly agreement, MeiraGTx received an upfront payment of $75 million and is eligible to receive over $400 million in total milestone payments, plus tiered royalties on licensed products. Lilly gained exclusive rights to AAV-AIPL1, two preclinical ocular programs, intravitreal capsids, bespoke promoters, and certain rights to MeiraGTx's riboswitch platform in the eye.
AI-Enhanced Drug Development
The company also entered into a strategic collaboration with Hologen Limited (search), forming the joint venture Hologen Neuro AI Ltd with a $200 million upfront payment to MeiraGTx. Hologen's multi-modal generative AI foundation models were specifically built to remove noise from clinical data and allow real clinical effects of treatment to be clearly seen.
"The use of Hologen's AI technology applied to MeiraGTx's statistically significant double-blind Phase 2 data-sets has de-risked the AAV-GAD program and identified disease modifying changes in the physiology of the brain in response to treatment," Forbes explained. The collaboration includes additional committed funding of up to $230 million to fully fund development of the AAV-GAD program through approval.
Parkinson's Disease Program Advances
In 2025, the FDA granted RMAT designation to AAV-GAD for treating Parkinson's disease (search) not adequately controlled with medication. The designation was based on positive data demonstrating statistically significant efficacy in three clinical studies: a Phase 1 dose escalation study (n=14), a double-blind sham-surgery controlled Phase 2 study (n=45), and a double-blind sham-surgery controlled Phase 1/2 clinical bridging study (n=14).
MeiraGTx is currently engaging with clinical trial sites globally and expects to initiate the pivotal Phase 3 double-blind sham-controlled study of AAV-GAD in the coming months at global centers of excellence in Parkinson's disease (search) treatment.
Riboswitch Platform Development
The company is advancing its proprietary Riboswitch gene regulation technology platform, which provides precise dosing of proteins, hormones, or peptides encoded by DNA via in vivo production in direct dose response to oral small molecule inducers. MeiraGTx is progressing its first riboswitch program into the clinic in metabolic disease with native human leptin (Ribo-leptin (search)).
This addresses a significant unmet need in patients with inherited and acquired leptin deficiency (search). The only currently available treatment, metreleptin, is immunogenic and can lead to neutralizing antibodies against leptin, resulting in catastrophic and potentially lethal metabolic consequences. The company is in iterative discussions with the FDA to open a Ribo-leptin (search) IND later this year.
Financial Position and Outlook
As of December 31, 2025, MeiraGTx had cash and cash equivalents of approximately $65.9 million. Combined with strategic partnership payments and receivables, the company believes it will have sufficient capital to fund operating expenses and capital expenditure requirements into the second half of 2027.
The company reported license revenue of $75.0 million for 2025 due to the upfront license fee payment under the Lilly collaboration agreement, compared to no license revenue in 2024. Net loss attributable to ordinary shareholders was $114.2 million, or $1.42 per share, compared to $147.8 million, or $2.12 per share, for 2024.